-
UGT1 Related Products (3)
Related Products (3)
-
UGT1A1-IN-1
0 ImagesUGT1A1-IN-1 is a UGT1A1 inhibitor and fluorescent probe (Ex=370 nm, Em=520 nm), with an IC50 of 1.33 μM and a Ki of 5.02 μM. UGT1A1-IN-1 is selectively glucuronidated by UGT1A1 at the bilirubin homologous binding site, and its PET effect is blocked along with this reaction, triggering fluorescence changes. UGT1A1-IN-1 can serve as a substitute for bilirubin to detect UGT1A1 activity and perform high-throughput screening of UGT1A1 modulators.
-
Yangambin
0 ImagesYangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases.
-
Human UGT1A4
0 ImagesCat. No.: HY-E72107Human UGT1A4 is a UDP-glucuronosyltransferase. Human UGT1A4 is the major enzyme catalyzing the glucuronidation of 25-hydroxyvitamin D3 (HY-32351) in the liver, and maintains vitamin D homeostasis by clearing 25-hydroxyvitamin D3. Human UGT1A4 regulates the substrate-dependent enzymatic activities of UGT1A1 and UGT1A6, while its own activity is also subject to substrate-dependent regulation by co-expressed UGT1A1 and UGT1A6.
